{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:16:29Z","timestamp":1792696589197,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["VICI09150182310010"],"award-info":[{"award-number":["VICI09150182310010"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Microbiol Biotechnol"],"DOI":"10.1007\/s00253-025-13580-5","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:17:20Z","timestamp":1755616640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Eumycetoma: pathogenesis, current treatments, and the search for new drugs"],"prefix":"10.1007","volume":"109","author":[{"given":"Dounia El","family":"Yachioui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Baltussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy W. J.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"3","key":"13580_CR1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2214\/ajr.180.3.1800665","volume":"180","author":"ME Abd El Bagi","year":"2003","unstructured":"Abd El Bagi ME (2003) New radiographic classification of bone involvement in pedal mycetoma. AJR Am J Roentgenol 180(3):665\u2013668","journal-title":"AJR Am J Roentgenol"},{"key":"13580_CR2","doi-asserted-by":"publisher","unstructured":"Abugessaisa I, Konings M, Manabe R-I, Kawashima T, Hasegawa A, Takahashi C, Tagami M, Okazaki Y, Lim W, Verbon A, Fahal AH, Kasukawa T, van de Sande WWJ (2022) Iron regulatory pathways differentially expressed during Madurella mycetomatis grain development in Galleria mellonella. bioRxiv:2022.12.20.520897. https:\/\/doi.org\/10.1101\/2022.12.20.520897","DOI":"10.1101\/2022.12.20.520897"},{"issue":"9","key":"13580_CR3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1473-3099(04)01131-4","volume":"4","author":"AO Ahmed","year":"2004","unstructured":"Ahmed AO, van Leeuwen W, Fahal A, van de Sande W, Verbrugh H, van Belkum A (2004) Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis 4(9):566\u2013574","journal-title":"Lancet Infect Dis"},{"key":"13580_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01723-17","author":"SA Ahmed","year":"2018","unstructured":"Ahmed SA, Gonz\u00e1lez GM, Tirado-S\u00e1nchez A, Moreno-L\u00f3pez LM, de Hoog S, Bonifaz A (2018) Nigrograna mackinnonii, not Trematosphaeria grisea (syn., Madurella grisea), is the main agent of black grain eumycetoma in Latin America. J Clin Microbiol. https:\/\/doi.org\/10.1128\/JCM.01723-17","journal-title":"J Clin Microbiol"},{"issue":"4","key":"13580_CR5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000142334","volume":"54","author":"C Borelli","year":"2008","unstructured":"Borelli C, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, Tiemann R, Tietjen K, Fugmann B, Lang-Fugmann S, Korting HC (2008) Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi. Chemotherapy 54(4):245\u2013259","journal-title":"Chemotherapy"},{"issue":"7","key":"13580_CR6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4161\/viru.25906","volume":"4","author":"N Browne","year":"2013","unstructured":"Browne N, Heelan M, Kavanagh K (2013) An analysis of the structural and functional similarities of insect hemocytes and mammalian phagocytes. Virulence 4(7):597\u2013603","journal-title":"Virulence"},{"issue":"2","key":"13580_CR7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008123","volume":"14","author":"JA C\u00e1rdenas-de la Garza","year":"2020","unstructured":"C\u00e1rdenas-de la Garza JA, Welsh O, Cu\u00e9llar-Barboza A, Suarez-S\u00e1nchez KP, De la Cruz-Valadez E, Cruz-G\u00f3mez LG, Gallardo-Rocha A, Ocampo-Candiani J, Vera-Cabrera L (2020) Clinical characteristics and treatment of actinomycetoma in northeast Mexico: a case series. PLoS Negl Trop Dis 14(2):e0008123","journal-title":"PLoS Negl Trop Dis"},{"key":"13580_CR8","unstructured":"CDC (2024a) Clinical Overview of Mycetoma. PUblisher. https:\/\/archive.cdc.gov\/www_cdc_gov\/fungal\/diseases\/mycetoma\/health-professionals.html#:~:text=Eumycetoma%20is%20less%20responsive%20to,cultured%20from%20lesions%20post%2Dtreatment. Accessed 25\/03 2025"},{"key":"13580_CR9","unstructured":"CDC (2024b) Mycetoma Basics. PUblisher. https:\/\/www.cdc.gov\/mycetoma\/about\/index.html Accessed 25\/03 2025"},{"key":"13580_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myae044","author":"JE Clark","year":"2024","unstructured":"Clark JE, Kim HY, van de Sande WWJ, McMullan B, Verweij P, Alastruey-Izquierdo A, Chakrabarti A, Harrison TS, Bongomin F, Hay RJ, Oladele R, Heim J, Beyer P, Galas M, Siswanto S, Dagne DA, Roitberg F, Gigante V, Beardsley J, Sati H, Alffenaar JW, Morrissey CO (2024) Eumycetoma causative agents: a systematic review to inform the World Health Organization priority list of fungal pathogens. Med Mycol. https:\/\/doi.org\/10.1093\/mmy\/myae044","journal-title":"Med Mycol"},{"key":"13580_CR11","unstructured":"ClinicalTrials.gov (2015) F901318 Single Ascending Dose Study in Healthy Male Volunteers. PUblisher. https:\/\/www.clinicaltrials.gov\/study\/NCT02142153?cond=olorofim&page=2&rank=16&tab=results. Accessed 01-08-2025"},{"key":"13580_CR12","unstructured":"ClinicalTrials.gov (2024) Olorofim Aspergillus Infection Study (OASIS). PUblisher. https:\/\/www.clinicaltrials.gov\/study\/NCT05101187?cond=olorofim&page=1&rank=1. Accessed 01-08-2025"},{"issue":"10","key":"13580_CR13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003232","volume":"8","author":"Y Crabol","year":"2014","unstructured":"Crabol Y, Poiree S, Bougnoux ME, Maunoury C, Barete S, Zeller V, Arvieux C, Pineau S, Amazzough K, Lecuit M, Lanternier F, Lortholary O, French Mycosis Study G (2014) Last generation triazoles for imported eumycetoma in eleven consecutive adults. PLoS Negl Trop Dis 8(10):e3232","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"13580_CR14","doi-asserted-by":"crossref","first-page":"11926","DOI":"10.1038\/s41598-018-30158-6","volume":"8","author":"N Dogra","year":"2018","unstructured":"Dogra N, Kumar A, Mukhopadhyay T (2018) Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep 8(1):11926","journal-title":"Sci Rep"},{"key":"13580_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/trae093","author":"SO El-Amin","year":"2024","unstructured":"El-Amin SO, El-Amin RO, El-Sadig SM, Fahal AH, Musa A (2024) Painful mycetoma: a study to understand the risk factors in patients visiting the Mycetoma Research Centre (MRC) in Khartoum, Sudan. Trans R Soc Trop Med Hyg. https:\/\/doi.org\/10.1093\/trstmh\/trae093","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8","key":"13580_CR16","volume":"14","author":"LYM Elkheir","year":"2020","unstructured":"Elkheir LYM, Haroun R, Mohamed MA, Fahal AH (2020) Madurella mycetomatis causing eumycetoma medical treatment: the challenges and prospects. PLoS Negl Trop Dis 14(8):e0008307","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"13580_CR17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008397","volume":"14","author":"D Emery","year":"2020","unstructured":"Emery D, Denning DW (2020) The global distribution of actinomycetoma and eumycetoma. PLoS Negl Trop Dis 14(9):e0008397","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"13580_CR18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011736","volume":"17","author":"AH Fahal","year":"2023","unstructured":"Fahal AH, Bakhiet SM (2023) Mycetoma and the environment. PLoS Negl Trop Dis 17(11):e0011736","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"13580_CR19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.trstmh.2010.11.008","volume":"105","author":"AH Fahal","year":"2011","unstructured":"Fahal AH, Rahman IA, El-Hassan AM, Rahman ME, Zijlstra EE (2011) The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg 105(3):127\u2013132","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"13580_CR20","doi-asserted-by":"crossref","first-page":"e0003679","DOI":"10.1371\/journal.pntd.0003679","volume":"9","author":"A Fahal","year":"2015","unstructured":"Fahal A, el Mahgoub S, El Hassan AM, Abdel-Rahman ME (2015) Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan. PLoS Negl Trop Dis 9(3):e0003679","journal-title":"PLoS Negl Trop Dis"},{"key":"13580_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed3030097","author":"AH Fahal","year":"2018","unstructured":"Fahal AH, Suliman SH, Hay R (2018) Mycetoma: the spectrum of clinical presentation. Trop Med Infect Dis. https:\/\/doi.org\/10.3390\/tropicalmed3030097","journal-title":"Trop Med Infect Dis"},{"issue":"11","key":"13580_CR22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S1473-3099(24)00404-3","volume":"24","author":"AH Fahal","year":"2024","unstructured":"Fahal AH, Ahmed ES, Bakhiet SM, Bakhiet OE, Fahal LA, Mohamed AA, Mohamedelamin ESW, Bahar MEN, Attalla HY, Siddig EE, Mhmoud NA, Musa AM, van de Sande WWJ, Scherrer B, Oyieko P, Egondi TW, Onyango KO, Hata K, Chu WY, Dorlo TPC, Br\u00fcggemann RJ, Nyaoke BA, Strub-Wourgaft N, Zijlstra EE (2024) Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial. Lancet Infect Dis 24(11):1254\u20131265","journal-title":"Lancet Infect Dis"},{"key":"13580_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jof10050345","author":"A Feuss","year":"2024","unstructured":"Feuss A, Bougnoux ME, Dannaoui E (2024) The role of Olorofim in the treatment of filamentous fungal infections: a review of in vitro and in vivo studies. J Fungi. https:\/\/doi.org\/10.3390\/jof10050345","journal-title":"J Fungi"},{"key":"13580_CR24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpra.2024.02.002","volume":"40","author":"MDA Gismalla","year":"2024","unstructured":"Gismalla MDA, Bakhiet MY, Alshareef AM, Saadeldien MSM, Ahmed GMA, Adam AMI, Abuelnour AEK (2024) Reconstructive surgery for mycetoma: preliminary algorithm and a systematic review. JPRAS Open 40:130\u2013137","journal-title":"JPRAS Open"},{"issue":"10","key":"13580_CR25","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/trstmh\/trab076","volume":"115","author":"R Hassan","year":"2021","unstructured":"Hassan R, Simpson H, Cano J, Bakhiet S, Ganawa E, Argaw D, Newport MJ, Deribe K, Fahal AH (2021) Modelling the spatial distribution of mycetoma in Sudan. Trans R Soc Trop Med Hyg 115(10):1144\u20131152","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"13580_CR26","unstructured":"Herrick EJ, Patel P, Hashmi MF (2025) Antifungal ergosterol synthesis inhibitors. In: StatPearls. \nhttps:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551581\/"},{"issue":"3","key":"13580_CR27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057774","volume":"8","author":"AI Ibrahim","year":"2013","unstructured":"Ibrahim AI, El Hassan AM, Fahal A, van de Sande WW (2013) A histopathological exploration of the Madurella mycetomatis grain. PLoS One 8(3):e57774","journal-title":"PLoS One"},{"issue":"7","key":"13580_CR28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003926","volume":"9","author":"W Kloezen","year":"2015","unstructured":"Kloezen W, van Helvert-van PM, Fahal AH, van de Sande WW (2015) A Madurella mycetomatis grain model in Galleria mellonella larvae. PLoS Negl Trop Dis 9(7):e0003926","journal-title":"PLoS Negl Trop Dis"},{"key":"13580_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myad118","author":"M Konings","year":"2023","unstructured":"Konings M, Eadie K, Strepis N, Nyuykonge B, Fahal AH, Verbon A, van de Sande WWJ (2023) The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo. Med Mycol. https:\/\/doi.org\/10.1093\/mmy\/myad118","journal-title":"Med Mycol"},{"issue":"2","key":"13580_CR30","first-page":"149","volume":"16","author":"I Kyriakidis","year":"2017","unstructured":"Kyriakidis I, Tragiannidis A, Munchen S, Groll AH (2017) Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf 16(2):149\u2013165","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"13580_CR31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","volume":"26","author":"R Laniado-Labor\u00edn","year":"2009","unstructured":"Laniado-Labor\u00edn R, Cabrales-Vargas MN (2009) Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26(4):223\u2013227","journal-title":"Rev Iberoam Micol"},{"issue":"4","key":"13580_CR32","volume":"12","author":"W Lim","year":"2018","unstructured":"Lim W, Melse Y, Konings M, Phat Duong H, Eadie K, Laleu B, Perry B, Todd MH, Ioset JR, van de Sande WWJ (2018) Addressing the most neglected diseases through an open research model: the discovery of fenarimols as novel drug candidates for eumycetoma. PLoS Negl Trop Dis 12(4):e0006437","journal-title":"PLoS Negl Trop Dis"},{"key":"13580_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myac003","author":"W Lim","year":"2022","unstructured":"Lim W, Konings M, Parel F, Eadie K, Strepis N, Fahal A, Verbon A, van de Sande WWJ (2022) Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella. Med Mycol. https:\/\/doi.org\/10.1093\/mmy\/myac003","journal-title":"Med Mycol"},{"issue":"2","key":"13580_CR34","doi-asserted-by":"crossref","first-page":"e0010159","DOI":"10.1371\/journal.pntd.0010159","volume":"16","author":"W Lim","year":"2022","unstructured":"Lim W, Nyuykonge B, Eadie K, Konings M, Smeets J, Fahal A, Bonifaz A, Todd M, Perry B, Samby K, Burrows J, Verbon A, van de Sande W (2022) Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma. PLoS Negl Trop Dis 16(2):e0010159","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"13580_CR35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/17460441.2022.2080195","volume":"17","author":"W Lim","year":"2022","unstructured":"Lim W, Verbon A, van de Sande W (2022) Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an open source drug discovery approach. Expert Opin Drug Discov 17(6):641\u2013659","journal-title":"Expert Opin Drug Discov"},{"key":"13580_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myad070","author":"J Ma","year":"2023","unstructured":"Ma J, Konings M, Verbon A, van de Sande WWJ (2023) A Falciformispora senegalensis grain model in Galleria mellonella larvae. Med Mycol. https:\/\/doi.org\/10.1093\/mmy\/myad070","journal-title":"Med Mycol"},{"issue":"11","key":"13580_CR37","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.3390\/ijms25116227","volume":"25","author":"J Ma","year":"2024","unstructured":"Ma J, Eadie K, Schippers M, Fahal A, Laleu B, Verbon A, van de Sande WWJ (2024) Novel compound MMV1804559 from the global health priority box exhibits in vitro and in vivo activity against Madurella mycetomatis. Int J Mol Sci 25(11):6227. https:\/\/doi.org\/10.3390\/ijms25116227","journal-title":"Int J Mol Sci"},{"issue":"6","key":"13580_CR38","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jac\/dkaf133","volume":"80","author":"J Ma","year":"2025","unstructured":"Ma J, Eadie K, Konings M, Fahal A, Verbon A, Van de Sande WJ (2025) Ibrexafungerp prolongs survival and reduces theeumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma. J Antimicrob Chemother 80(6):1733\u20131741. https:\/\/doi.org\/10.1093\/jac\/dkaf133","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"13580_CR39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1254\/fpj.153.79","volume":"153","author":"M Nakano","year":"2019","unstructured":"Nakano M, Aoki Y, Yamaguchi H (2019) [Drug properties of fosravuconazole L-lysine ethanolate (NAILIN(\u00ae) capsules 100\u2005mg), a new oral azole therapeutic for onychomycosis: an analysis based on non-clinical and clinical trial data]. Nihon Yakurigaku Zasshi 153(2):79\u201387","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"2","key":"13580_CR40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-4632.2004.02392.x","volume":"45","author":"B N\u2019Diaye","year":"2006","unstructured":"N\u2019Diaye B, Dieng MT, Perez A, Stockmeyer M, Bakshi R (2006) Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol 45(2):154\u2013157","journal-title":"Int J Dermatol"},{"issue":"6","key":"13580_CR41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1590\/S0036-46652005000600006","volume":"47","author":"R Negroni","year":"2005","unstructured":"Negroni R, Tob\u00f3n A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A (2005) Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 47(6):339\u2013346","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"10","key":"13580_CR42","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/jdv.13008","volume":"29","author":"P Nenoff","year":"2015","unstructured":"Nenoff P, van de Sande WW, Fahal AH, Reinel D, Sch\u00f6fer H (2015) Eumycetoma and actinomycetoma\u2013an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy. J Eur Acad Dermatol Venereol 29(10):1873\u20131883","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"13580_CR43","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jdv.18642","volume":"37","author":"B Nyuykonge","year":"2023","unstructured":"Nyuykonge B, Siddig E, Mhmoud NA, Bakhiet S, Zijlstra E, Verbon A, Fahal AH, van de Sande WWJ (2023) Wako \u03b2-D-glucan assay can be used to measure serum \u03b2-D-glucan in Sudanese patients to aid with diagnosis of eumycetoma caused by Madurella mycetomatis. J Eur Acad Dermatol Venereol 37(4):783\u2013786","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"13580_CR44","doi-asserted-by":"crossref","DOI":"10.1111\/myc.13664","volume":"67","author":"B Nyuykonge","year":"2024","unstructured":"Nyuykonge B, Siddig EE, Nyaoke BA, Zijlstra EE, Verbon A, Bakhiet SM, Fahal AH, van de Sande WWJ (2024) Using (1,3)-\u03b2-D-glucan concentrations in serum to monitor the response of azole therapy in patients with eumycetoma caused by Madurella mycetomatis. Mycoses 67(1):e13664","journal-title":"Mycoses"},{"issue":"Suppl 39","key":"13580_CR45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","volume":"126","author":"NS Ryder","year":"1992","unstructured":"Ryder NS (1992) Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 126(Suppl 39):2\u20137","journal-title":"Br J Dermatol"},{"issue":"4","key":"13580_CR46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008190","volume":"14","author":"G Sheehan","year":"2020","unstructured":"Sheehan G, Konings M, Lim W, Fahal A, Kavanagh K, van de Sande WWJ (2020) Proteomic analysis of the processes leading to Madurella mycetomatis grain formation in Galleria mellonella larvae. PLoS Negl Trop Dis 14(4):e0008190","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"13580_CR47","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.13561","volume":"66","author":"EE Siddig","year":"2023","unstructured":"Siddig EE, Nyuykonge B, Mhmoud NA, Abdallah OB, Bahar MEN, Ahmed ES, Nyaoke B, Zijlstra EE, Verbon A, Bakhiet SM, Fahal AH, van de Sande WWJ (2023) Comparing the performance of the common used eumycetoma diagnostic tests. Mycoses 66(5):420\u2013429","journal-title":"Mycoses"},{"issue":"8","key":"13580_CR48","volume":"14","author":"G Singh","year":"2020","unstructured":"Singh G, Agarwal R, Khullar S, Xess I, Sharma VK, Goyal A (2020) Recalcitrant eumycetoma of the foot: Financial burden a major barrier on the road of recovery. PLoS Negl Trop Dis 14(8):e0008356","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"13580_CR49","volume":"15","author":"D Sow","year":"2020","unstructured":"Sow D, Ndiaye M, Sarr L, Kant\u00e9 MD, Ly F, Diouss\u00e9 P, Faye BT, Gaye AM, Sokhna C, Ranque S, Faye B (2020) Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018. PLoS One 15(4):e0231871","journal-title":"PLoS One"},{"issue":"9","key":"13580_CR50","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1164\/rccm.201211-2069OC","volume":"188","author":"F Tissot","year":"2013","unstructured":"Tissot F, Lamoth F, Hauser PM, Orasch C, Fl\u00fcckiger U, Siegemund M, Zimmerli S, Calandra T, Bille J, Eggimann P, Marchetti O, Fungal Infection Network of S (2013) \u03b2-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 188(9):1100\u20131109","journal-title":"Am J Respir Crit Care Med"},{"key":"13580_CR51","unstructured":"Todd M (2025) Benzoxazoles manuscript writing #5. PUblisher. https:\/\/github.com\/OpenSourceMycetoma\/series-5-benzimidazoles\/issues\/5. Accessed 26 Mar 2025"},{"issue":"4","key":"13580_CR52","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/AAC.01045-10","volume":"55","author":"A van Belkum","year":"2011","unstructured":"van Belkum A, Fahal AH, van de Sande WW (2011) In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother 55(4):1771\u20131773","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"13580_CR53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/trstmh\/traa184","volume":"115","author":"WWJ van de Sande","year":"2021","unstructured":"van de Sande WWJ (2021) In vitro susceptibility testing for black grain eumycetoma causative agents. Trans R Soc Trop Med Hyg 115(4):343\u2013354","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"13580_CR54","volume":"37","author":"WWJ van de Sande","year":"2024","unstructured":"van de Sande WWJ, Fahal AH (2024) An updated list of eumycetoma causative agents and their differences in grain formation and treatment response. Clin Microbiol Rev 37(2):e0003423","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"13580_CR55","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.micinf.2007.05.015","volume":"9","author":"WW van de Sande","year":"2007","unstructured":"van de Sande WW, de Kat J, Coppens J, Ahmed AO, Fahal A, Verbrugh H, van Belkum A (2007) Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect 9(9):1114\u20131123","journal-title":"Microbes Infect"},{"issue":"3","key":"13580_CR56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002667","volume":"8","author":"WW van de Sande","year":"2014","unstructured":"van de Sande WW, el Maghoub S, Fahal AH, Goodfellow M, Welsh O, Zijlstra E (2014) The mycetoma knowledge gap: identification of research priorities. PLoS Negl Trop Dis 8(3):e2667","journal-title":"PLoS Negl Trop Dis"},{"key":"13580_CR57","doi-asserted-by":"crossref","unstructured":"van de Sande W, Fahal A, Ahmed SA, Serrano JA, Bonifaz A, Zijlstra E, eumycetoma working g (2018) Closing the mycetoma knowledge gap. Med Mycol 56(suppl_1):153\u2013164","DOI":"10.1093\/mmy\/myx061"},{"issue":"10","key":"13580_CR58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005007","volume":"10","author":"A Wadal","year":"2016","unstructured":"Wadal A, Elhassan TA, Zein HA, Abdel-Rahman ME, Fahal AH (2016) Predictors of post-operative mycetoma recurrence using machine-learning algorithms: the mycetoma research center experience. PLoS Negl Trop Dis 10(10):e0005007","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"13580_CR59","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","volume":"56","author":"NA Watanabe","year":"2012","unstructured":"Watanabe NA, Miyazaki M, Horii T, Sagane K, Tsukahara K, Hata K (2012) E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother 56(2):960\u2013971","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"13580_CR60","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1517\/14656566.2013.842553","volume":"14","author":"O Welsh","year":"2013","unstructured":"Welsh O, Vera-Cabrera L, Salinas-Carmona MC (2013) Current treatment for Nocardia infections. Expert Opin Pharmacother 14(17):2387\u20132398","journal-title":"Expert Opin Pharmacother"},{"key":"13580_CR61","unstructured":"WHO (2016) Assessing the burden of mycetoma. WHO Geneva (WHA69.21). https:\/\/iris.who.int\/handle\/10665\/252801"},{"issue":"11","key":"13580_CR62","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.trstmh.2012.07.003","volume":"106","author":"HA Zein","year":"2012","unstructured":"Zein HA, Fahal AH, el Mahgoub S, El Hassan TA, Abdel-Rahman ME (2012) Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan. Trans R Soc Trop Med Hyg 106(11):639\u2013644","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"13580_CR63","volume":"10","author":"J Zhang","year":"2019","unstructured":"Zhang J, Li L, Lv Q, Yan L, Wang Y, Jiang Y (2019) The fungal CYP51s: their functions, structures, related drug resistance, and inhibitors. Front Microbiol 10:691","journal-title":"Front Microbiol"},{"issue":"1","key":"13580_CR64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1473-3099(15)00359-X","volume":"16","author":"EE Zijlstra","year":"2016","unstructured":"Zijlstra EE, van de Sande WWJ, Welsh O, Mahgoub ES, Goodfellow M, Fahal AH (2016) Mycetoma: a unique neglected tropical disease. Lancet Infect Dis 16(1):100\u2013112","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"13580_CR65","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-2008-1063858","volume":"29","author":"DI Zonios","year":"2008","unstructured":"Zonios DI, Bennett JE (2008) Update on azole antifungals. Semin Respir Crit Care Med 29(2):198\u2013210","journal-title":"Semin Respir Crit Care Med"}],"container-title":["Applied Microbiology and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-025-13580-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00253-025-13580-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00253-025-13580-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:33:48Z","timestamp":1770294828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00253-025-13580-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13580"],"URL":"https:\/\/doi.org\/10.1007\/s00253-025-13580-5","relation":{},"ISSN":["1432-0614"],"issn-type":[{"value":"1432-0614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}